【レポートの概要（一部）】
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: Global Market 2016-2026
3.1 The Global Respiratory Drugs Market by Therapeutic Area
3.2 The Global Asthma and COPD Therapies Market in 2016
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2016-2026
3.3.1 Global Asthma Therapies Market: Sales Forecast, 2016-2026
3.3.2 Global COPD Therapies Market: Sales Forecast 2016-2026
3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2016-2026
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Shares Change to 2026
3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2016-2026
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Bronchodilator Monotherapy Market 2016-2026
4.1 Introduction to Bronchodilator Monotherapy
4.2 The Bronchodilator Monotherapy Market in 2015
4.2.1 Leading Bronchodilators in 2015
4.2.2 Bronchodilator Monotherapy: Market Forecast 2016-2026
4.2.3 How Will Market Shares by Drug Class Change to 2026?
4.3 The Anticholinergics Market 2016-2026
4.3.1 Leading Anticholinergics in 2015
4.3.2 Anticholinergics: Market Forecast 2016-2026
4.3.3 Market Share of Leading Anticholinergics to 2026
4.3.4 Spiriva (tiotropium. Boehringer Ingelheim)
4.3.4.1 Spiriva: Sales Forecast 2016-2026
4.3.4.2 Spiriva: Recent Developments
4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
4.3.5.1 Atrovent: Sales Forecast 2016-2026
4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2016-2026
4.4 The SABAs Market 2016-2016
4.4.1 Leading SABAs in 2015
4.4.2 SABAs: Market Forecast 2016-2026
4.4.3 Market Share of Leading SABAs to 2026
4.4.4 Ventolin (salbutamol, GSK)
4.4.4.1 Ventolin: Sales Forecast 2016-2026
4.4.5 ProAir (salbutamol, Teva)
4.4.5.1 ProAir: Sales Forecast 2016-2026
4.4.6 Proventil (salbutamol, Merck)
4.4.6.1 Proventil: Sales Forecast 2016-2026
4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
4.4.7.1 Xopenex: Sales Forecast 2016-2026
4.5 The Long-Acting Beta2-Agonist (LABA) Market 2016-2026
4.5.1 Leading LABAs in 2015
4.5.2 LABAs: Market Forecast 2016-2026
4.5.3 Market Share of Leading LABAs to 2026
4.5.4 Foradil (formoterol, Merck/Novartis
4.5.4.1 Foradil: Sales Forecast 2016-2026
4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
4.5.5.1 Brovana: Sales Forecast 2016-2026
4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
4.5.6.1 Arcapta/Onbrez: Sales Forecast 2016-2026
4.5.7 Severent (salmeterol, GSK)
4.5.7.1 Serevent: Sales Forecast 2016-2026
5. Anti-inflammatory Drugs Market 2016-2026
5.1 Introduction to Anti-Inflammatory Drugs
5.2 The Anti-Inflammatory Drugs Market in 2015
5.2.1 Leading Anti-Inflammatory Drugs in 2015
5.2.2 Anti-Inflammatory Drugs: Market Forecast 2016-2026
5.2.3 How Will Market Shares by Drug Class Change to 2026?
5.3 The Corticosteroids Market 2016-2026
5.3.1 Leading Corticosteroids in 2015
5.3.2 Corticosteroids: Market Forecast 2016-2026
5.3.3 Market Share of Leading Corticosteroids to 2026
5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
5.3.4.1 Flixotide/Flovent: Sales Forecast 2016-2026
5.3.5 Pulmicort (budesonide, AstraZeneca)
5.3.5.1 Pulmicort: Sales Forecast 2016-2026
5.3.6 QVAR (beclometasone, Teva)
5.3.6.1 QVAR: Sales Forecast 2016-2026
5.3.7 Asmanex (mometasone, Merck)
5.3.7.1 Asmanex: Sales Forecast 2016-2026
5.4 The Anti-Leukotrienes Market 2016-2026
5.4.1 Leading Anti-Leukotrienes in 2015
5.4.2 Anti-Leukotrienes: Market Forecast 2016-2026
5.4.3 Market Share of Leading Anti-Leukotrienes to 2026
5.4.4 Singulair (montelukast, Merck)
5.4.4.1 Singulair: Sales Forecast 2016-2026
5.5 The Monoclonal Antibodies Market 2016-2026
5.5.1 Monoclonal Antibodies: Market Forecast 2016-2026
5.5.2 Market Share of Leading Monoclonal Antibodies to 2026
5.5.3 Xolair (omalizumab, Novartis/Roche)
5.5.3.1 Xolair: Sales Forecast 2016-2026
5.5.4 Cinquil (reslizumab, Teva)
5.5.4.1 Cinquil: Sales Forecast 2016-2026
5.5.5 Nucala (Mepolizumab, GSK)
5.5.5.1 Nucala: Sales Forecast 2016-2026
5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
5.5.6.1 Benralizumab: Sales Forecast 2016-2026
5.5.7 Lebrikizumab (RG3637, Roche)
5.5.7.1 Lebrikizumab: Sales Forecast 2016-2026
5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
5.5.8.1 Dupilumab: Sales Forecast 2016-2026
6. Combination Drugs Market 2016-2026
6.1 Introduction to Combination Drugs
6.1.1 Leading Combination Drugs in 2015
6.1.2 Combination Drugs: Market Forecast 2016-2026
6.1.3 How Will Market Shares by Drug Change to 2026?
6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
6.1.4.1 Advair/Seretide: Sales Forecast 2016-2026
6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
6.1.5.1 Symbicort: Sales Forecast 2016-2026
6.1.5.2 Symbicort: The SMART Concept
6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
6.1.6.1 Combivent: Sales Forecast 2016-2026
6.1.7 Dulera (formoterol/mometasone, Merck)
6.1.7.1 Dulera: Sales Forecast 2016-2026
6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
6.1.8.1 Breo/Relvar: Sales Forecast 2016-2026
6.2 Recently Launched Combination Drugs
7. Leading National Markets 2016-2026
7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2016-2026
7.2.1 How Will Regional Market Shares Change to 2026?
7.2.2 National Breakdown of the Global asthma and COPD Therapies Market
7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2016-2026
7.2.4 How Will National Market Shares Change to 2026?
7.3 The US Asthma and COPD Therapies Market 2016-2026
7.3.1 The US Asthma and COPD Therapies Market Forecast 2016-2026
7.3.2 US Asthma and COPD Therapies Market Trends and Developments
7.3.2.1 Increasing COPD Prevalence in the US
7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
7.4 Japanese Asthma and COPD Therapies Market 2016-2026
7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2016-2026
7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
7.4.2.1 Is Generic Penetration to Reach 60% by 2018?
7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
7.5 EU5 Asthma and COPD Therapies Market 2016-2026
7.5.1 German Asthma and COPD Therapies Market Forecast 2016-2026
7.5.2 French Asthma and COPD Therapies Market Forecast 2016-2026
7.5.3 UK Asthma and COPD Therapies Market Forecast 2016-2026
7.5.4 Italian Asthma and COPD Therapies Market Forecast 2016-2026
7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2016-2026
7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
7.5.6.2 France: Social Security Finance Bill 2015
7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes
7.5.6.4 Italy: Austerity Measures Limiting Growth
7.5.6.5 Spain: The Start of Recovery in the Spanish Economy
7.6 BRIC Asthma and COPD Therapies Market 2016-2026
7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2016-2026
7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
7.6.2.1 China’s Industrial Future and Asthma/COPD
7.6.2.2 Expansion of Healthcare Coverage and Reimbursement
7.6.2.3 Price Controls and the Anhui Model
7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
7.6.4.1 Increasing Access to Medicines
7.6.5 Indian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
7.6.6.1 Drug Prices Control Order 2013
7.6.6.2 Expansion of Healthcare Provision
7.6.7 Russian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
7.6.8.1 No Embargo on Foreign Drug Imports
7.6.8.2 Pharma2020 and the Russian Pharmaceutical Industry
7.7 Mexican Asthma and COPD Therapies Market 2016-2026
7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2016-2026
7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
7.7.2.1 Seguro Popular: Mexican Healthcare Reform
7.7.2.2 COFEPRIS: Regulatory Changes and Improvements
7.7.2.3 Mexico’s Agreement for Innovation
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.2 Leading Companies in Asthma and COPD in 2015
8.3 Leading Companies: Market Forecast 2016-2026
8.4 How Will Leading Companies’ Market Shares Change to 2026?
8.5 GSK
8.5.1 GSK: Asthma and COPD Therapies
8.5.2 GSK: Sales Forecast 2016-2026
8.5.3 GSK: Products in Development
8.5.4 GSK: Recent Developments
8.5.4.1 Recently Launched Combination Drugs
8.5.4.2 GSK Divests OTC Products
8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.6.2 Boehringer Ingelheim: Sales Forecast 2016-2026
8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.6.4 Boehringer Ingelheim: Recent Developments
8.6.4.1 Expansion of Respimat Manufacturing Capacity
8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.6.4.3 Ben Venue Laboratories Shut Down
8.6.4.4 Sale of Roxane Laboratories
8.6.4.5 Spiloto Respimat and the PHYSACTO Study
8.7 AstraZeneca
8.7.1 AstraZeneca: Asthma and COPD Therapies
8.7.2 AstraZeneca: Sales Forecast 2016-2026
8.7.3 AstraZeneca: Products in Development
8.7.4 AstraZeneca: Recent Developments
8.7.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.7.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
8.7.4.5 Takeda Respiratory Portfolio Acquisition
8.8 Merck & Co. (Merck)
8.8.1 Merck: Asthma and COPD Therapies
8.8.2 Merck: Sales Forecast 2016-2026
8.8.3 Merck: Products in Development
8.8.4 Merck: Recent Developments
8.8.4.1 Bayer Acquires Merck’s Consumer Health Business
8.8.4.2 FDA Rejects Singulair OTC Switch
8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.9 Novartis
8.9.1 Novartis: Asthma and COPD Therapies
8.9.2 Novartis: Sales Forecast 2016-2026
8.9.3 Novartis: Products in Development
8.9.4 Novartis: Recent Developments
8.9.4.1 Novartis Restructures Following Strategic Review
8.9.4.2 Novartis Presents Data on Ultibro and Seebri
8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.10 Roche
8.10.1 Roche: Asthma and COPD Therapies
8.10.2 Roche: Sales Forecast 2016-2026
8.10.3 Roche: Products in Development
8.11 Teva
8.11.1 Teva: Asthma and COPD Therapies
8.11.2 Teva: Sales Forecast 2016-2026
8.11.3 Teva: Products in Development
8.11.4 Teva: Recent Developments
8.11.4.1 Launch of DuoResp Spiromax
9. Asthma and COPD Therapies Pipeline Analysis 2016-2026
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.3 Bronchodilators: Phase 3 Pipeline
9.3.1 PX1439 and PX1442 (Prosonix)
9.3.2 PT001 (glycopyrronium, AstraZeneca)
9.3.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.3.4 GW642444 (vilanterol, GSK)
9.3.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.3.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.3.7 QVAR BAI (beclometasone, Teva)
9.3.8 Albuterol MDPI/Albuterol RespiClick (salbutamol, Teva)
9.4 The Anti-Inflammatory Drugs Pipeline
9.5 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.5.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.5.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.5.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.5.4 VR506 (fluticasone propionate DPI, Vectura)
9.5.5 Favolir (budesonide, Vectura)
9.6 The Combination Drugs Pipeline
9.7 Combination Drugs: Phase 3 Pipeline
9.7.1 Seriveo (fluticasone/salmeterol, Circassia) (Formerly PSX2005 (Prosonix))
9.7.2 Duaklir Genuair (LAS40464) (aclidinium/formoterol, AstraZeneca)
9.7.3 Bevespi Aerosphere (PT003) (glycopyrronium/formoterol, AstraZeneca)
9.7.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.7.5 Easyhaler Combination Drugs (Orion)
9.7.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.8 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2016-2026
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.3 Ultra-Long-Acting Beta2-Agonists
10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.5 Monoclonal Antibodies
10.4.6 LAMA/LABA Combinations
10.4.7 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
11. Conclusions
11.1 Asthma and COPD Therapies: A Maturing Market
11.2 The Global Asthma and COPD Therapies Market in 2015
11.3 Current Leading Asthma and COPD Therapies Segments
11.3.1 Leading Asthma and COPD Therapies
11.3.2 Leading Asthma and COPD Therapies Companies
11.4 Leading Regional and National Markets
11.5 Global Asthma and COPD Therapies Market Forecast 2016-2026
11.6 The Future of the Asthma and COPD Therapies Market
11.6.1 Growth in Anti-Inflammatory and Combination Drugs
11.6.2 Personalised Medicine
11.6.3 Unmet Needs in Asthma and COPD
11.7 Strategies for Growth in 2016-2026
12. Glossary
【レポート販売概要】
■ タイトル：喘息＆COPDの世界市場2016-2026■ 英文：Asthma & COPD Market Report 2016-2026
■ 発行日：2016年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN61125
■ 調査対象地域：グローバル
- 植物性肉の世界市場展望2017-2026According to Stratistics MRC, the Global Plant-Based Meat Market is accounted for $8.96 billion in 2017 and is expected to reach $34.61 billion by 2026 growing at a CAGR of 16.2% during the forecast period. Increasing number of consumers are demanding plant-based meat, either for medical reasons or as a healthy lifestyle and continuous efforts in research & development by plant-based meat manufact …
- 免疫療法用治療薬の世界市場：単クローン抗体、インターフェロンα、インターロイキン、ワクチン、チェックポイント阻害薬The immunotherapy drugs market is expected to grow at a CAGR of 12.8% to reach USD 73,529.2 Million by 2020. The growing focus on cancer therapies with fewer side effects is a key factor driving the growth of the global immunotherapy drugs market. Other factors driving the market include high prevalence rate of lifestyle diseases including cancer, fast track and orphan drug designations expediting …
- 石油・ガスのインフラセキュリティ市場予測（2014-2024）The oil and gas infrastructure security market will experience steady growth over the next 10 years. The unconventional oil and gas boom, the expansion of the LNG infrastructure supply chain, continued offshore developments and the emergence of the digital oilfield are all prime factors for new security solution spending. Visiongain has assessed that global expenditure on oil and gas infrastructur …
- 認知障害：グローバル臨床試験レビュー（2014年上半期）Cognitive Impairment Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Cognitive Impairment Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment. It includes an overview of the trial numbers and their r …
- パワーエレクトロニクスの世界市場：パワーディスクリートデバイス、パワーモジュール、パワーICAbout power electronics Power electronics is the use of solid-state electronics for the control and conversion of electrical energy. Most of the electronic systems are concerned with the transmission and processing of data and signals. These power electronic devices have high power efficiency, high blocking voltage, and the ability to work on low power. The most typical power electronic device is …
- 医療用ロボットの世界市場：手術ロボット、福祉ロボット、非侵襲性放射線手術ロボット、病院/薬局ロボットRobotics in Healthcare – new study showing you trends, R&D progress, and predicted revenues Where’s the robotics in healthcare market heading? Visiongain’s brand new report shows you potential revenues and volume sales to 2025, assessing data, trends, opportunities and prospects there. Our 194-page report provides 109 tables, charts, and graphs. Discover the most lucrative areas in the industry an …
- オンライン会議サービスの世界市場：WEB会議サービス、テレビ会議サービスAbout Online Corporate Meeting Services Online corporate meeting has changed the way of business communication in organizations. It is the most attractive choice for organization to hold active online meetings and make contact with others instantly when communication is required. Online corporate meeting services comprise of communication services through video conferencing services and web confer …
- Sexually-Transmitted Diseases in Japan 2014: Market Outlook and Emerging OpportunitiesAbout This ReportThis new 280-page report from Venture Planning Group presents detailed analysis of the Japanese STD market, including sales forecasts and supplier shares for Chancroid, Chlamydia, Gonorrhea, Herpes (I/II, VI), Papillomavirus (Pap Smear, HPV), and Syphilis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition …
- 分子量マーカーの世界市場分析、製品別（DNA、タンパク質、RNAマーカー）、用途別（PCR、シークエンシング、ノーザンブロッティング、サザンブロッティング、分子クローニング、ウェスタンブロッティング、ゲル抽出）、タイプ別、セグメント予測、2014-2025The global molecular weight marker market is expected to reach a value of USD 1.1 billion by 2025, according to a new report by Grand View Research, Inc. Increasing investment in R&D by companies including biotechnology and biologics is the major factor that drives the growth during the forecast period. These markers are used by researchers and companies for various applications such as polymerase …
- 世界の幹細胞製品市場動向（2012-2016）TechNavio’s analysts forecast the Global Stem Cell Products market to grow at a CAGR of 12.17 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant advancements in R&D. The Global Stem Cell Products market has also been witnessing new regulations for regenerative medicine in the EMEA region. However, the lack of specialists in this domain c …
- 陸地地震装置および取得の世界市場2016-2026The land seismic equipment and acquisition markets are important to follow as spending and trends within these markets indicate future locations for drilling and resource exploitation. The oil price collapse has caused a sharp decline in land seismic acquisition contract awards and CAPEX on equipment. Visiongain expects spending to recover gradually in line with the anticipated oil price recovery, …
- 世界のFTTx通信市場：市場分析と予測（～2018）n/a
- 遠隔医療サービス産業におけるIT支出市場：Telehealth、mHealthAbout IT spending in remote healthcare delivery Affordable healthcare is the right of the citizens of a country. However, delivering quality healthcare to all their citizens is one of the challenges faced by all governments. The problem is common to both developing nations as well as developed nations. The only difference is the extent of the problem. In regions such as the Americas, quality healt …
- 世界のパワーディスクリート（Power Discrete）市場動向（2014-2018）TechNavio's analysts forecast the Global Power Discrete market to grow at a CAGR of 8.43 percent over the period 2013-2018. One of the key factors contributing to this market growth is the high demand for discrete IGBTs. The Global Power Discrete market has also been witnessing the emerging market for SiC and GaN power semiconductors. However, the low demand due to global economic slowdown could p …
- グローバル個人衛生用品市場におけるM&A動向（2014年3月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global personal hygiene market during March 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global personal hygiene market throughout the month. Additionally, the report provides an overview of …
